Timolol (Ganfort, Ganfort Ud, Combigan)
Timolol
Abbvie (Pty) Ltd
Registration
- Applicant
- Abbvie (Pty) Ltd
- Certificate holder
- Abbvie (Pty) Ltd
- Registrations
- 3
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Ganfort EACH 1,0 ml SOLUTION CONTAINS: BIMATOPROST 0,3 mg,TIMOLOL MALEATE EQUIVALENT TO TIMOLOL 5,0 mg | 0,3 mg/mlEye drops, solution | 42012742/15.4/0127Approved 21 April 2023 | Registered | Not determined | PIPIL |
| Ganfort ud EACH 1,0 ml SOLUTION CONTAINS: BIMATOPROST 0,3 mg TIMOLOL MALEATE EQUIVALENT TO TIMOLOL 5,0 mg | Not listed | 59007959/15.4/0079 | Registered | Not determined | None |
| Combigan EACH 1,0 ml SOLUTION CONTAINS :BRIMONIDINE TARTRATE 2,0 mg, TIMOLOL MALEATE EQUIVALENT TO TIMOLOL 5,0 mg | 2 mg/ml + 5 mg/mlOphthalmic solution | A390464A39/15.4/0464Approved 17 February 2025 | Registered | Not determined | PIPIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Bimatoprost
Consolidated Schedules 06 July 2026, line 5499
S4: Latanoprost
Consolidated Schedules 06 July 2026, line 6878
S4: Travoprost
Consolidated Schedules 06 July 2026, line 8272
S3: Brinzolamide
Consolidated Schedules 06 July 2026, line 3235
S3: Dorzolamide
Consolidated Schedules 06 July 2026, line 3486
S3: Timolol
Consolidated Schedules 06 July 2026, line 4325
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(2S)-1-(tert-Butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
Drag to rotate. Structure from PubChem CID 33624.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.